AZD9150 plus Durvalumab alone or in Combination with Chemotherapy in Patients with Advanced, Solid Tumours and in Patients with Non-Small-Cell Lung Cancer

Study identifier:D5660C00016

ClinicalTrials.gov identifier:NCT03421353

EudraCT identifier:2017-004925-34

CTIS identifier:N/A

Study Complete

Official Title

A Phase Ib/II, Open-Label, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 plus Durvalumab alone or in Combination with Chemotherapy in Patients with Advanced, Solid Tumours and Subsequently in Patients with Non-Small-Cell Lung Cancer

Medical condition

Advanced Solid Tumours

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD9150, Durvalumab, Cisplatin, 5-Flourouracil, Carboplatin, Gemcitabine, Nab-paclitaxel

Sex

All

Actual Enrollment

76

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 07 Feb 2018
Primary Completion Date: 17 Jan 2020
Study Completion Date: 28 Mar 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria